Next quarter’s earnings estimate for EQ is -$0.05 with a range of -$0.05 to -$0.05. The previous quarter’s EPS was -$0.06. EQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year EQ has Performed in-line its overall industry.
Next quarter’s earnings estimate for EQ is -$0.05 with a range of -$0.05 to -$0.05. The previous quarter’s EPS was -$0.06. EQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year EQ has Performed in-line its overall industry.
EQ Sales Forecast
Next quarter’s sales forecast for EQ is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. EQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year EQ has Performed in-line its overall industry.
Next quarter’s sales forecast for EQ is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. EQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year EQ has Performed in-line its overall industry.
Equillium's Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial UncertaintiesWe also note that EQ recently announced a cryptocurrency treasury reserve strategy earlier this month, but has yet to begin the initiative – we expect EQ's focus going forward will be on the advancement and development of '504, rather than the crypto treasury strategy. Overall, we see the private placement as a fundamental positive for EQ shares –removing a near-term financing overhang and reflecting investor optimism for AhR modulators as a promising class of therapeutics & a vote of confidence in EQ’s emerging pipeline strategy with EQ504 in IBD.
Equillium's Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial UncertaintiesWe also note that EQ recently announced a cryptocurrency treasury reserve strategy earlier this month, but has yet to begin the initiative – we expect EQ's focus going forward will be on the advancement and development of '504, rather than the crypto treasury strategy. Overall, we see the private placement as a fundamental positive for EQ shares –removing a near-term financing overhang and reflecting investor optimism for AhR modulators as a promising class of therapeutics & a vote of confidence in EQ’s emerging pipeline strategy with EQ504 in IBD.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +10.90% per trade.
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -13.80% per trade.
Copying Roger Song's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -31.70% per trade.
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -44.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EQ Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
1
1
1
0
0
Buy
0
0
0
0
0
Hold
11
10
5
6
7
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
11
6
6
7
In the current month, EQ has received 0Buy Ratings, 7Hold Ratings, and 0Sell Ratings. EQ average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
EQ Stock Forecast FAQ
What is EQ’s average 12-month price target, according to analysts?
Currently, no data Available
What is EQ’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for EQ, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EQ a Buy, Sell or Hold?
Equillium Inc has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Equillium Inc’s price target?
Currently, no data Available
What do analysts say about Equillium Inc?
Equillium Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of EQ?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.